Competition. Some of our competitors have initiated clinical trials for GvHD, solid tumors and multiple myeloma, settings in which our iNKT cell therapy platform is currently being investigated. We are also aware of competitors pursuing cell therapy drug candidates, including but not limited to stem cell-based approaches, for the treatment of ARDS secondary to COVID-19. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies th...
Q2 FY2026 — expected 2026-09-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001193125-26-134813 | EDGAR | 74K words |
| 2025-03-18 | 2024-12-31 | 0000950170-25-041379 | EDGAR | — |
| 2024-03-21 | 2023-12-31 | 0000950170-24-034672 | EDGAR | — |
| 2023-03-24 | 2022-12-31 | 0000950170-23-009762 | EDGAR | — |
| 2022-03-18 | 2021-12-31 | 0001564590-22-011026 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001193125-25-282905 | EDGAR | 16K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108894 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0000950170-25-072789 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0000950170-24-127033 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096142 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059081 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0000950170-23-063851 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-040958 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021191 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0000950170-22-021565 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001564590-22-029503 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001564590-22-020146 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001193125-26-133346 | EDGAR | 1K words |
| 2026-03-27 | 0001193125-26-127931 | EDGAR | — |
| 2026-03-19 | 0001193125-26-116219 | EDGAR | — |
| 2026-01-02 | 0001193125-26-000916 | EDGAR | — |
| 2025-12-08 | 0001193125-25-311229 | EDGAR | — |
| 2025-09-29 | 0001193125-25-221863 | EDGAR | — |
| 2025-08-14 | 0001171843-25-005405 | EDGAR | — |
| 2025-07-15 | 0001193125-25-159017 | EDGAR | — |
| 2025-07-14 | 0000950170-25-095460 | EDGAR | — |
| 2025-06-18 | 0000950170-25-087888 | EDGAR | — |
70 total filings indexed. 43 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001840229 |
| Ticker | INKT |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.minktherapeutics.com |
| Listed | 2021-10-15 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/INKT (~200 tokens, structured JSON with cryptographic provenance)